SCHEMBL1127495

SCHEMBL1127495

CCOC(=O)C(C(=O)OCC)C(=O)C(Cc1cc(F)cc(F)c1)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 5/20 0.38
MME P08473 1/20 0.37
KDM4E B2RXH2 4/20 0.36
CYP1A2 P05177 1/20 0.36
S1PR3 Q99500 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PKM P14618 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
LMNA P02545 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPC1 O15118 2/20 0.34
NOS2 P35228 1/20 0.34
RAB9A P51151 1/20 0.34
CASP1 P29466 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127494 0.91 KMT2A (0.51) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL1127316 0.87 MEN1 (0.52) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL4281403 0.87 KMT2A (0.46) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL12627632 0.85 ALDH1A1 (0.37) KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL1127307 0.84 KMT2A (0.49) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL1127390 0.83 KMT2A (0.48) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL1127497 0.82 ALDH1A1 (0.36) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL1127315 0.82 MEN1 (0.47) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL1127831 0.81 KMT2A (0.45) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL1127508 0.81 GAA (0.46) KMT2AMEN1GAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF KMT2A 2735/4885MEN1 4723/4885GAA 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.